Mark Scapens
Direktor/Vorstandsmitglied bei CANNASOUTH LIMITED
Aktive Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Peng Ho | M | 65 | 6 Jahre | |
| Christine Pears | F | - | 3 Jahre | |
| Tony Clark | M | - | - | |
| David Gill | M | - | 5 Jahre | |
| Hilary Webber | F | - |
Eqalis Pharmaceuticals Ltd
 Eqalis Pharmaceuticals Ltd Pharmaceuticals: MajorHealth Technology Part of Cannasouth Ltd., Eqalis Pharmaceuticals Ltd is a New Zealander company that manufactures cannabis-based pharmaceuticals. The company is based in Katikati, New Zealand. The CEO of the company is Greg Misson. Eqalis Pharmaceuticals was acquired by Cannasouth Ltd. on May 24, 2023 for $27.30 million. | - |
| Greg Misson | M | - |
Eqalis Pharmaceuticals Ltd
Eqalis Pharmaceuticals Ltd Pharmaceuticals: MajorHealth Technology Part of Cannasouth Ltd., Eqalis Pharmaceuticals Ltd is a New Zealander company that manufactures cannabis-based pharmaceuticals. The company is based in Katikati, New Zealand. The CEO of the company is Greg Misson. Eqalis Pharmaceuticals was acquired by Cannasouth Ltd. on May 24, 2023 for $27.30 million. | - |
| Richard Nash | M | - |
Eqalis Pharmaceuticals Ltd
Eqalis Pharmaceuticals Ltd Pharmaceuticals: MajorHealth Technology Part of Cannasouth Ltd., Eqalis Pharmaceuticals Ltd is a New Zealander company that manufactures cannabis-based pharmaceuticals. The company is based in Katikati, New Zealand. The CEO of the company is Greg Misson. Eqalis Pharmaceuticals was acquired by Cannasouth Ltd. on May 24, 2023 for $27.30 million. | - |
| Pierre Booysen | M | - | - |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Statistik
| Land | Beziehungen | % des Gesamten |
|---|---|---|
| Neuseeland | 8 | 100,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Mark Scapens
- Persönliches Netzwerk